[
    "ptide receptors such as for \n\n somatostatin, vasoactive intestinales peptide (VIP), luteinising hormone-releasing hormone (LHRH), bombesin (BN), gastrin-releasing-peptide (GRP), cholecystoki- nin (CCK), substance P (SP), neurotensin (NT), neuropeptide Y (NPY), \u03b1- melanocyte stimulating hormone (\u03b1-MSH), vitamin receptors such as the folate receptor, folate reduced carrier, vitamin D receptors, retinoid binding proteins, ca- balamin binding proteins and their receptors, riboflavin carrier proteins, binding proteins for tocopherol, ascorbic acid, thiamine and vitamin, biotin binding proteins, vascular receptors such as vascular endothelial growth factor receptors (VEGFR-1/VEGFR-2), integrins, e.g. \u03b1v\u03b23, \u03b1v\u03b25, \u03b15\u03b21 , Tie-2, CD44 receptor, aminopeptidase N, aminopeptidase P, NG2 proteoglycan, ED-B, vessel marker for LyP-1 , endothelial leucocyte cell adhesion molecule-1 (E-selectin), vascular cell adhesion molecule-1 (VCAM-1 ), endoglin, E-cadherin, receptors such as the asialoglycoprotein receptor, scavenging receptors and the LDL receptor, apopto- sis-inducing tumor necrosis factor (TNF) family receptors, Fas receptor (CD95), TRAIL receptors (TRAIL-R1 , TRAIL-R2, TRAIL-R3 and TRAIL-R4), CanAg receptor, N-cadherin, or antigens such as carcinoembryonic antigen (CEA), tissue polypeptide antigen (TPA), colon-specific antigen-p, prostate-specific membrane antigen (PSMA) CA 19-9, CA 15.3, CA 72-4, CA 50; CA 125, CA 195, DuPAN-2, SCC-A/Ta-4, SP 4, Ly-2.1 , L6, SL-2Ly, EIy-Ly, Lewis-Y, Ki-67 antigen, SART3 tumor antigen, MCA and other breast cancer associated mucinous glycoproteins, CD1 to CD150, especially CD4, CD8, CD19, CD20, CD21 , CD22, CD29, CD33, CD44, CD46, CD55, CD56, CD59, CD 63, CD87 and CD95.</p>Another embodiment of the present invention relates to the prodrug as defined above, wherein the receptor and/or antigen targeting moiety is derived from a peptide, a peptidomimetic, a sugar, a vitamin or a lipid. The ligand attached to the prodrug can contain one or more of said molecules that are connected in a linear, cyclic and/or branched manner.</p>According to a preferred embodiment, the receptor and/or antigen moiety of the above-defined prodrug comprises a folic acid derivative. \n\n According to another preferred embodiment, the receptor and/or antigen moiety of the above-defined prodrug comprises a sugar cluster, for example a GaI- and/or GalNAc-cluster.</p>According to another preferred embodiment, the receptor and/or antigen moiety of the above-defined prodrug comprises one or more peptide derivatives, for example, SPLWRNSVL, TSPLNIHNGQKL, MYWGDSHWLQYWYE, MCPKHPLGC, HLQIQPWYPQIS, HEWSYLAPYPWF, KCCYSL, CESLWGGLMWTIGLSDC, CNIWGVVLSWIGVFPEC, LTVGPWG, CDRGDCFC (RGD-4C), ACDCRGDCFCG, CNGRCVSGCAGRC, CVCNGRMEC, NGRAHA, CGSLVRC, CGLSDSC, TAASGVRSMH, LTLRWVGLMS, CTTHWGFTLC,</p>NRSLKRISNKRIRRK, RRKRRR, ATWLPPR, CPGPEGAGC, SMSIARL, VSFLEYR, PRPGAPLAGSWPGTS, DRWRPALPVVLFPLH,</p>ASSSYPLIHWRPWAR, HTMYYHHYQHHL, CGNKRTRGC, CGNRTRGC, NGEIEWYSWVTHGMY, CCDRGDCFC"
]